New drug combination for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug combination for people with advanced solid tumors. It aims to see if the combination is safe and may shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You need to be in general good health – able to do light activities and take care of yourself.
- If you have HIV or hepatitis, it must be well-controlled with medication and undetectable virus levels.
- You must not have received cancer treatment in the last 4 weeks.
- You cannot be on steroids or other immune-suppressing medicines.
- Your cancer must not have spread to the brain or spinal cord.
- You must not have had lung inflammation (pneumonitis) or scarring of the lungs that needed steroids.
- You must not have had serious bleeding or coughed up blood in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new drug, MK-2010, alone or with other treatments for people with advanced solid tumors. The goal is to learn if it is safe and effective. Participants should be in fairly good health despite their cancer.
This study tests a new drug combination for people with advanced solid tumors that have not responded to other treatments. It aims to see if the combination is safe and effective.
This trial tests a new drug called sacituzumab tirumotecan combined with immunotherapy for people with advanced thyroid cancer that cannot be removed by surgery or has spread. It aims to see if this combination can help shrink tumors or slow down the cancer.
This trial tests a combination of two newer drugs (sacituzumab tirumotecan and anlotinib) for people with extensive-stage small cell lung cancer that has progressed after one prior treatment. The goal is to see if this combination can shrink tumors and help patients live longer.
This trial is testing a new drug called MK-2870, alone or with other treatments, for people with advanced colorectal, pancreatic, or bile duct cancer. It aims to see if the drug can help shrink or control the cancer.
This trial tests two new study drugs (SCTB41 and SCTB39-1) given together, sometimes with standard treatment, to see if they are safe and effective against advanced solid tumors. If you join, you will receive these drugs and be monitored for how well they fight the cancer.
Hear when a new Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.